首页> 美国卫生研究院文献>AAPS PharmSciTech >Development of Sustained Release Capsules Containing Coated Matrix Granules of Metoprolol Tartrate
【2h】

Development of Sustained Release Capsules Containing Coated Matrix Granules of Metoprolol Tartrate

机译:含有酒石酸美托洛尔包衣基质颗粒的缓释胶囊的研制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The objective of this investigation was to prepare sustained release capsule containing coated matrix granules of metoprolol tartrate and to study its in vitro release and in vivo absorption. The design of dosage form was performed by choosing hydrophilic hydroxypropyl methyl cellulose (HPMC K100M) and hydrophobic ethyl cellulose (EC) polymers as matrix builders and Eudragit® RL/RS as coating polymers. Granules were prepared by composing drug with HPMC K100M, EC, dicalcium phosphate by wet granulation method with subsequent coating. Optimized formulation of metoprolol tartrate was formed by using 30% HPMC K100M, 20% EC, and ratio of Eudragit® RS/RL as 97.5:2.5 at 25% coating level. Capsules were filled with free flowing optimized granules of uniform drug content. This extended the release period upto 12 h in vitro study. Similarity factor and mean dissolution time were also reported to compare various dissolution profiles. The network formed by HPMC and EC had been coupled satisfactorily with the controlled resistance offered by Eudragit® RS. The release mechanism of capsules followed Korsemeyer–Peppas model that indicated significant contribution of erosion effect of hydrophilic polymer. Biopharmaceutical study of this optimized dosage form in rabbit model showed 10 h prolonged drug release in vivo. A close correlation (R2 = 0.9434) was established between the in vitro release and the in vivo absorption of drug. The results suggested that wet granulation with subsequent coating by fluidized bed technique, is a suitable method to formulate sustained release capsules of metoprolol tartrate and it can perform therapeutically better than conventional immediate release dosage form.
机译:该研究的目的是制备含有酒石酸美托洛尔的包衣基质颗粒的缓释胶囊,并研究其体外释放和体内吸收。通过选择亲水性羟丙基甲基纤维素(HPMC K100M)和疏水性乙基纤维素(EC)聚合物作为基质助洗剂以及Eudragit®RL / RS作为包衣聚合物来进行剂型设计。通过将药物与HPMC K100M,EC,磷酸二钙通过湿法制粒方法组成并随后包衣来制备颗粒。通过使用30%HPMC K100M,20%EC和25%涂料水平下RS / RL的比例为97.5:2.5来形成酒石酸美托洛尔的优化配方。胶囊填充有均匀药物含量的自由流动的优化颗粒。这将释放期延长至长达12小时的体外研究。还报道了相似因子和平均溶解时间以比较各种溶解曲线。 HPMC和EC组成的网络已与Eudragit®RS提供的受控电阻令人满意地耦合在一起。胶囊的释放机理遵循Korsemeyer-Peppas模型,表明亲水性聚合物的腐蚀作用显着。这种优化剂型在兔模型中的生物药物研究表明,其体内药物释放时间延长了10小时。在药物的体外释放与体内吸收之间建立了密切的相关性(R 2 = 0.9434)。结果表明,湿法制粒并随后通过流化床技术进行包衣是配制酒石酸美托洛尔缓释胶囊的合适方法,并且其治疗效果优于常规速释剂型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号